Your browser doesn't support javascript.
Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine.
Bastard, Paul; Michailidis, Eleftherios; Hoffmann, Hans-Heinrich; Chbihi, Marwa; Le Voyer, Tom; Rosain, Jérémie; Philippot, Quentin; Seeleuthner, Yoann; Gervais, Adrian; Materna, Marie; de Oliveira, Patricia Mouta Nunes; Maia, Maria de Lourdes S; Dinis Ano Bom, Ana Paula; Azamor, Tamiris; Araújo da Conceição, Deborah; Goudouris, Ekaterini; Homma, Akira; Slesak, Günther; Schäfer, Johannes; Pulendran, Bali; Miller, Joseph D; Huits, Ralph; Yang, Rui; Rosen, Lindsey B; Bizien, Lucy; Lorenzo, Lazaro; Chrabieh, Maya; Erazo, Lucia V; Rozenberg, Flore; Jeljeli, Mohamed Maxime; Béziat, Vivien; Holland, Steven M; Cobat, Aurélie; Notarangelo, Luigi D; Su, Helen C; Ahmed, Rafi; Puel, Anne; Zhang, Shen-Ying; Abel, Laurent; Seligman, Stephen J; Zhang, Qian; MacDonald, Margaret R; Jouanguy, Emmanuelle; Rice, Charles M; Casanova, Jean-Laurent.
  • Bastard P; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France.
  • Michailidis E; University of Paris, Imagine Institute, Paris, France.
  • Hoffmann HH; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY.
  • Chbihi M; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY.
  • Le Voyer T; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY.
  • Rosain J; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France.
  • Philippot Q; University of Paris, Imagine Institute, Paris, France.
  • Seeleuthner Y; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France.
  • Gervais A; University of Paris, Imagine Institute, Paris, France.
  • Materna M; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France.
  • de Oliveira PMN; University of Paris, Imagine Institute, Paris, France.
  • Maia MLS; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France.
  • Dinis Ano Bom AP; University of Paris, Imagine Institute, Paris, France.
  • Azamor T; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France.
  • Araújo da Conceição D; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France.
  • Goudouris E; University of Paris, Imagine Institute, Paris, France.
  • Homma A; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France.
  • Slesak G; University of Paris, Imagine Institute, Paris, France.
  • Schäfer J; Bio-Manguinhos, Fiocruz, Ministry of Health, Rio de Janeiro, Brazil.
  • Pulendran B; Bio-Manguinhos, Fiocruz, Ministry of Health, Rio de Janeiro, Brazil.
  • Miller JD; Laboratory of Immunological Techniques, Bio-Manguinhos, Fiocruz, Ministry of Health, Rio de Janeiro, Brazil.
  • Huits R; Laboratory of Immunological Techniques, Bio-Manguinhos, Fiocruz, Ministry of Health, Rio de Janeiro, Brazil.
  • Yang R; Bio-Manguinhos, Fiocruz, Ministry of Health, Rio de Janeiro, Brazil.
  • Rosen LB; Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
  • Bizien L; Bio-Manguinhos, Fiocruz, Ministry of Health, Rio de Janeiro, Brazil.
  • Lorenzo L; Tropical Medicine Department, Tropenklinik Paul-Lechler-Krankenhaus, Tübingen, Germany.
  • Chrabieh M; Tropical Medicine Department, Tropenklinik Paul-Lechler-Krankenhaus, Tübingen, Germany.
  • Erazo LV; Emory Vaccine Center and the Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA.
  • Rozenberg F; Institute for Immunity, Transplantation and Infection, Department of Pathology, Department of Microbiology and Immunology, Stanford University, Stanford, CA.
  • Jeljeli MM; Emory Vaccine Center and the Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA.
  • Béziat V; Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Scientific Resources, Atlanta, GA.
  • Holland SM; Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
  • Cobat A; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY.
  • Notarangelo LD; Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
  • Su HC; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France.
  • Ahmed R; University of Paris, Imagine Institute, Paris, France.
  • Puel A; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France.
  • Zhang SY; University of Paris, Imagine Institute, Paris, France.
  • Abel L; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France.
  • Seligman SJ; University of Paris, Imagine Institute, Paris, France.
  • Zhang Q; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France.
  • MacDonald MR; Laboratory of Virology, University of Paris, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Jouanguy E; Laboratory of Immunology, University of Paris, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Rice CM; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France.
  • Casanova JL; University of Paris, Imagine Institute, Paris, France.
J Exp Med ; 218(4)2021 04 05.
Article in English | MEDLINE | ID: covidwho-1066211
Semantic information from SemMedBD (by NLM)
1. Disease PROCESS_OF Patients
Subject
Disease
Predicate
PROCESS_OF
Object
Patients
2. Patients LOCATION_OF IFNAR1 gene|IFNAR1
Subject
Patients
Predicate
LOCATION_OF
Object
IFNAR1 gene|IFNAR1
3. yellow fever vaccine PART_OF Virus
Subject
yellow fever vaccine
Predicate
PART_OF
Object
Virus
4. Yellow fever virus ADMINISTERED_TO Healthy Volunteers
Subject
Yellow fever virus
Predicate
ADMINISTERED_TO
Object
Healthy Volunteers
5. Disease PROCESS_OF Patients
Subject
Disease
Predicate
PROCESS_OF
Object
Patients
6. Patients LOCATION_OF IFNAR1 gene|IFNAR1
Subject
Patients
Predicate
LOCATION_OF
Object
IFNAR1 gene|IFNAR1
7. yellow fever vaccine PART_OF Virus
Subject
yellow fever vaccine
Predicate
PART_OF
Object
Virus
8. Yellow fever virus ADMINISTERED_TO Healthy Volunteers
Subject
Yellow fever virus
Predicate
ADMINISTERED_TO
Object
Healthy Volunteers
ABSTRACT
Yellow fever virus (YFV) live attenuated vaccine can, in rare cases, cause life-threatening disease, typically in patients with no previous history of severe viral illness. Autosomal recessive (AR) complete IFNAR1 deficiency was reported in one 12-yr-old patient. Here, we studied seven other previously healthy patients aged 13 to 80 yr with unexplained life-threatening YFV vaccine-associated disease. One 13-yr-old patient had AR complete IFNAR2 deficiency. Three other patients vaccinated at the ages of 47, 57, and 64 yr had high titers of circulating auto-Abs against at least 14 of the 17 individual type I IFNs. These antibodies were recently shown to underlie at least 10% of cases of life-threatening COVID-19 pneumonia. The auto-Abs were neutralizing in vitro, blocking the protective effect of IFN-α2 against YFV vaccine strains. AR IFNAR1 or IFNAR2 deficiency and neutralizing auto-Abs against type I IFNs thus accounted for more than half the cases of life-threatening YFV vaccine-associated disease studied here. Previously healthy subjects could be tested for both predispositions before anti-YFV vaccination.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Autoantibodies / Autoimmune Diseases / Yellow fever virus / Interferon-alpha / Yellow Fever Vaccine / Receptor, Interferon alpha-beta / Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Genetic Diseases, Inborn Topics: Vaccines Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: English Year: 2021 Document Type: Article Affiliation country: Jem.20202486

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Autoantibodies / Autoimmune Diseases / Yellow fever virus / Interferon-alpha / Yellow Fever Vaccine / Receptor, Interferon alpha-beta / Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Genetic Diseases, Inborn Topics: Vaccines Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: English Year: 2021 Document Type: Article Affiliation country: Jem.20202486